Skip to main content

Precision Pathology: A New Frontier for Diagnostic Pathology

Edited by:
Professor Anil Parwani, MD, PhD, MBA, The Ohio State University, United States of America
Professor Zaibo Li, MD, PhD, The Ohio State University Wexner Medical Center, United States of America  

Submission Status: Open   |   Submission Deadline: 9 December 2024


Diagnostic Pathology is calling for submissions to our Collection on Precision Pathology: A New Frontier for Diagnostic Pathology.

Image credit: © LALAKA / stock.adobe.com

About the Collection

In recent years, the field of pathology has undergone a remarkable transformation, driven by advancements in technologies and our growing understanding of diseases at a molecular level. One such technology is digital pathology which enables the digitization of histopathology slides, creating vast repositories of digital images that can be analysed, shared, and utilised for research, education and diagnostic purposes. Advanced image analysis algorithms and machine learning techniques are being employed to extract valuable information from these images, aiding pathologists in making more accurate and efficient diagnoses.

Precision pathology represents a shift in the way we diagnose, classify, and treat diseases. A key area of focus in precision pathology, is the utility of digital pathology and artificial intelligence as well as integration of genomic information into diagnostic and treatment decisions. By analysing the DNA and RNA profiles of tumours, researchers can identify specific genetic mutations, gene expression patterns, and molecular signatures that guide personalised treatment strategies. This can be effectively combined with AI-powered algorithms to create a “PRECISE” pathology diagnosis leading to customized treatments for individual patients, these insights allow for targeted therapies, resulting in better patient outcomes and reduced side effects.

This collection of articles aims to explore the exciting developments and opportunities that precision pathology brings to the forefront of healthcare. It will delve into topics such as genomics, proteomics, and computational-enabled precise pathology diagnostics, which are revolutionizing the way we analyse and interpret pathology specimens and data.

We hope that the articles featured in this collection will not only deepen your understanding of precision pathology but also inspire further research and collaboration, propelling us toward a future where personalised and targeted medicine becomes the standard of care.

  1. Warthin tumor (WT) is the second most common benign tumor in salivary gland. It has a slow growth rate and most frequently occurs in the parotid gland. Most patients present with an incidental finding of a pai...

    Authors: Hai-Chao Tong, Shuang Ma, Lan Chen, Xiangyun Meng, Ying-Chun Li, Le-Yao Li, Lingyun Dong, Wan-Lin Zhang, Tyler Wildes, Lian-He Yang and Endi Wang
    Citation: Diagnostic Pathology 2024 19:114
  2. CLDN is a core component of tight junctions (TJs). Abnormal expressions of CLDNs are commonly detected in various types of tumors. CLDNs are of interest as a potential therapeutic target. CLDNs are closely ass...

    Authors: Xiaojie Fan, Aifeng Qi, Meng Zhang, Ying Jia, Shi Li, Dandan Han and Yueping Liu
    Citation: Diagnostic Pathology 2024 19:113
  3. Compared to primary breast sarcoma (BSs), radiotherapy-induced sarcoma (RIS) is a less frequent type of secondary breast sarcoma. Undifferentiated pleomorphic sarcoma (UPS) is an even rarer occurrence within t...

    Authors: Ting Lei, Zhiyi Shen, Mengjia Shen, Lingfang Du, Yongqiang Shi, Yan Peng, Zidi Zhou, Wenyue Da, Xi Chen and Qing Li
    Citation: Diagnostic Pathology 2024 19:110
  4. Hepatocellular carcinoma (HCC) is a malignant tumor. It is estimated that approximately 50–80% of HCC cases worldwide are caused by hepatitis b virus (HBV) infection, and other pathogenic factors have been sho...

    Authors: Anyin Yang, Jianping Liu, Mengru Li, Hong Zhang, Xulei Zhang and Lianping Wu
    Citation: Diagnostic Pathology 2024 19:105

    The Correction to this article has been published in Diagnostic Pathology 2024 19:117

  5. There is currently scarcity of information on small cell neuroendocrine carcinoma of the nasopharynx (SCNEC-nasopharynx). It is believed that this type of cancer is not associated with Epstein-Barr virus (EBV)...

    Authors: Ying Chen, Ning Zhou, Caijun Huang, Xin He, Xiaodong Wang, Hao Tang, Wenyan Wang, Jiashuang Wang, Tao Li and Deyu Guo
    Citation: Diagnostic Pathology 2024 19:101
  6. Acinic cell carcinoma (AciCC) of the breast is a rare subtype of breast cancer. It was considered a low-grade triple-negative breast cancer (TNBC) with the potential to progress or transform into a high-grade ...

    Authors: Yunjie Ge, Xianping Wei, Jing-Nan Liu, Ping-Li Sun and Hongwen Gao
    Citation: Diagnostic Pathology 2024 19:100
  7. Immunohistochemistry (IHC) is widely used in the management of patients with cervical intraepithelial neoplasia (CIN) but still has many limitations in clinical practice. We analyzed the correlation of new bio...

    Authors: Shikang Qiu, Qiannan Wang, Huihui Jiang and Limin Feng
    Citation: Diagnostic Pathology 2024 19:97

Submission Guidelines

Back to top

This Collection welcomes submission of research articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Precision Pathology: A New Frontier for Diagnostic Pathology" under the “Details” tab during the submission stage.

Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.